The Phase II study of Velcade (Bortezomib) in Ph+ leukemia patients, particularly those resistant to imatinib, addresses a significant unmet medical need in the treatment of Chronic Myelogenous Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia. Given the limited efficacy of current therapies in patients who do not achieve a complete hematological response (CHR) or a complete cytogenetic response (CCgR) on imatinib, Bortezomib may offer a valuable alternative. The market for CML treatments is competitive, with established therapies such as imatinib and newer agents like dasatinib and nilotinib. However, the potential for Bortezomib to be positioned as a second-line treatment could enhance its commercial viability, especially if it demonstrates improved outcomes in resistant populations. The study's completion in 2008 suggests that data may be available for further analysis, which could inform future development strategies and partnerships.